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ABSTRACT
High levels of expression of glycoprotein non-metastatic B (gpNMB) in triple 
negative breast cancer (TNBC) and its association with metastasis and recurrence make 
it an attractive target for therapy with the antibody drug conjugate, glembatumumab 
vedotin (CDX-011). This report describes the development of a companion PET-based 
diagnostic imaging agent using 89Zr-labeled glembatumumab ([89Zr]DFO-CR011) to 
potentially aid in the selection of patients most likely to respond to targeted treatment 
with CDX-011. [89Zr]DFO-CR011 was characterized for its pharmacologic properties in 
TNBC cell lines. Preclinical studies determined that [89Zr]DFO-CR011 binds specifically 
to gpNMB with high affinity (Kd = 25 ± 5 nM), immunoreactivity of 2.2-fold less than 
the native CR011, and its cellular uptake correlates with gpNMB expression (r = 0.95). 
In PET studies at the optimal imaging timepoint of 7 days p.i., the [89Zr]DFO-CR011 
tumor uptake in gpNMB-expressing MDA-MB-468 xenografts had a mean SUV of 2.9, 
while significantly lower in gpNMB-negative MDA-MB-231 tumors with a mean SUV 
of 1.9. [89Zr]DFO-CR011 was also evaluated in patient-derived xenograft models of 
TNBC, where tumor uptake in vivo had a positive correlation with total gpNMB protein 
expression via ELISA (r = 0.79), despite the heterogeneity of gpNMB expression 
within the same group of PDX mice. Lastly, the radiation dosimetry calculated from 
biodistribution studies in MDA-MB-468 xenografts determined the effective dose for 
human use would be 0.54 mSv/MBq. Overall, these studies demonstrate that [89Zr]
DFO-CR011 is a potential companion diagnostic imaging agent for CDX-011 which 
targets gpNMB, an emerging biomarker for TNBC.
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 61), pp: 104303-104314
                                                     Research Paper
Oncotarget104304www.impactjournals.com/oncotarget
INTRODUCTION
The rise of companion diagnostic imaging agents, 
which are molecular imaging agents that provide 
information on the effective use of the corresponding 
drugs, is changing the paradigm of screening for targeted 
therapy in cancer. Companion diagnostics typically 
make use of in vitro testing of biopsied tissues using 
immunohistochemistry, fluorescence in situ hybridization, 
enzyme-linked immunosorbent assays, quantitative 
PCR, or DNA sequencing, among others [1]. While 
important for diagnosis, these techniques do not provide 
information on the location of therapeutic targets and the 
delivery of the therapeutic agents throughout the body. 
Nuclear imaging of the expression of therapeutic targets 
has the potential to identify patients who may benefit 
from such therapies while sparing patients unlikely to 
respond to unnecessary treatments. Several examples 
have demonstrated the potential of PET imaging using 
89Zr-labeled antibodies as companion diagnostic agents 
to (i) assess receptor targets in vivo especially in the 
metastatic setting, (ii) identify candidate patients for 
targeted therapy, and (iii) determine the overall safety of 
these imaging agents [2–4]. In breast cancer, [89Zr]DFO-
trastuzumab is paving the way towards the selection of 
the human epidermal growth factor receptor 2 (HER2)-
positive patients for therapeutic antibodies that target this 
receptor. While this companion diagnostic imaging agent 
shows promise in stratifying patients who may benefit 
from the already established HER2-targeted therapies, 
there is currently no such approach for patients with the 
triple negative breast cancer (TNBC) subtype.
TNBC is diagnosed by the absence of three receptors 
that can be targeted for therapy: HER2, estrogen receptor, 
and progesterone receptor. The current standard of care 
for patients diagnosed with TNBC is chemotherapy, but 
resistance to these treatments and early recurrence of 
disease are prevalent [5, 6]. TNBC patients are also more 
likely to develop metastases in the brain, bone, lung, and 
liver [7]. For these reasons, TNBC is more aggressive 
than other subtypes of breast cancer. However, targeted 
treatments in clinical trials are currently gaining traction 
to improve patient outcomes such as immune therapy and 
antibody drug conjugates (ADCs) [8, 9]. In general, ADCs 
deliver the drug payload specifically to cancer cells by 
binding to receptors that are overexpressed on the cancer 
cell surface, are internalized by the cell, and release the 
drug to kill the cell via different mechanisms specific 
for each type of ADC. ADCs have shown success in the 
treatment of the HER2-positive breast cancer subtype [10, 
11].
Using similar strategies to existing companion 
diagnostic imaging agents for the HER2-positive breast 
cancer subtype, we have developed a positron emission 
tomography (PET) agent for imaging gpNMB. This 
transmembrane glycoprotein is overexpressed in many 
malignancies [12–14]. gpNMB is expressed in ≥ 25% of 
tumor epithelial cells in about 40% of TNBC patients [9]. 
In most normal cells, gpNMB is expressed intracellularly, 
which permits greater selectivity for targeting malignant 
cells via the extracellular domain of this protein [15]. 
gpNMB is most commonly expressed in the basal-
like subtype of TNBC and has been found to promote 
metastasis and is linked to recurrence [12, 13]. Higher 
levels of gpNMB expression in TNBC are associated 
with worse metastasis-free survival and overall survival 
(OS). Preclinical studies in melanoma have shown that 
the level of gpNMB expression is proportional to the 
effectiveness of gpNMB-targeted therapy via an ADC 
called glembatumumab vedotin (CDX-011) [16, 17].
Previous clinical trials have demonstrated an 
acceptable safety profile of CDX-011 and improved 
progression-free survival (PFS) of patients with gpNMB-
positive breast cancer regardless of their subtype [9, 18]. 
In these studies, the greatest impact (objective response 
rate (ORR), PFS, and OS) of CDX-011 relative to the 
control arm was observed in patients with TNBC that 
expressed gpNMB. In the EMERGE trial, increasing 
levels of gpNMB expression (≥ 5% vs ≥ 25% positivity) 
are associated with higher response rates (15% vs 30%, 
respectively) to CDX-011 [9]. The efficacy of CDX-011 
is being compared to capecitabine in the ongoing phase II 
METRIC trial in patients with TNBC positive for gpNMB 
in >25% of tumor epithelium by IHC of an archival tumor 
material (NCT#01997333)[19]. Imaging gpNMB will 
provide a non-invasive means for identifying patients 
who may benefit from treatment with CDX-011. Taken 
together, the expression of gpNMB plays an important role 
in clinical outcome, making gpNMB an attractive target 
for imaging and therapy of TNBC.
In this report, we describe the development of a 
companion diagnostic imaging agent to image gpNMB in 
xenograft models of TNBC. Our approach is to radiolabel 
the naked antibody, glembatumumab (CR011), with a 
PET radionuclide, Zr-89 (t1/2 = 3.3 days). The sensitivity 
of PET combined with the decay properties of Zr-89 
could be advantageous in providing high resolution 
images and quantitative value in tracking the distribution 
of the antibody in vivo well into its clearance from the 
bloodstream [16]. Therefore, [89Zr]DFO-CR011 will 
provide a non-invasive, quantitative, and sensitive 
assessment of gpNMB expression in preclinical models 
of TNBC and eventually in clinical trials. In this work, 
we show the development of [89Zr]DFO-CR011 as a 
companion diagnostic imaging agent via preclinical 
evaluation to pre-qualify this PET agent for translation to 
clinical trial. Toward this end, we evaluated its specificity 
for gpNMB, immunoreactivity, stability, imaging quality, 
pharmacokinetic properties, and dosimetry; all of which 
are required for an investigational new drug (IND) 
application to the FDA.
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RESULTS
Characterization of [89Zr]DFO-CR011 in vitro
The ratio of DFO:CR011 was determined to be 4 
(Supplementary Figure 1), which is comparable to that 
of the drug:antibody ratio of 4 - 5 in CDX-011 [20–22]. 
The stability of [89Zr]DFO-CR011 was determined in 
buffer at ambient temperature for 24 hrs, as this time point 
under these conditions could be used to set an expiration 
time for injection into patients from the end of antibody 
radiolabeling. FPLC analysis showed the stability of 
[89Zr]DFO-CR011 with a retention time of 22.5 min, 
radiochemical purity of 100%, and antibody aggregation 
of 7% at t0 and 10% at 24 hrs (Supplementary Figure 2). 
This aggregation meets the specification of up to 20% 
aggregation based on the criterion used for the chemistry, 
manufacturing, and controls of an IND-approved [89Zr]-
trastuzumab, which means that an expiration time of 24 
hrs can be used for injection into patients [23]. Further, a 
serum stability study was performed in separate solutions 
of human and mouse sera up to 7 days, in vitro. We found 
that [89Zr]DFO-CR011 is more stable in human serum than 
in mouse serum. In human serum, [89Zr]DFO-CR011 was 
97% monomer initially, was maintained at 95% monomer 
at 5 days, and decreased to 67% at 7 days. In mouse 
serum, [89Zr]DFO-CR011 was 97% monomer initially, 
and decreased to 64, 59, and 57 % at 1, 5, and 7 days, 
respectively (Supplementary Figure 3).
[89Zr]DFO-CR011 was then characterized using 
various cell binding assays in vitro. Human TNBC cell 
lines were confirmed for cell surface expression of 
gpNMB using flow cytometry (Supplementary Figure 
4) and quantified total gpNMB expression from whole 
cell lysate using ELISA (Supplementary Table 1). MDA-
MB-157, MDA-MB-468, and MDA-MB-231 were 
determined to have high (11.1 ± 0.9 pg gpNMB/μg total 
protein), moderate (2.7 ± 0.1), and negligible (0.15 ± 0.05) 
expression of gpNMB, respectively (Supplementary Table 
1), which is in agreement with the flow cytometry results 
(Supplementary Figure 4). As a control, we used the 
SK-Mel2 human melanoma cells, as this cell line highly 
expresses gpNMB (6.8 ± 0.3) [17].
The immunoreactivity was determined using 
a competitive binding assay, where the DFO-CR011 
conjugate retained its antigen-binding property with a 
2.2-fold ratio between EC50 values for DFO-CR011 (EC50 
= 88 nM) and native CR011 (EC50 = 40 nM) (Figure 
1A). Additionally, the binding affinity (Kd) of [89Zr]
DFO-CR011 and copy number of gpNMB (Bmax) were 
determined via a radioligand saturation assay in SK-
Mel2, MDA-MB-157, and MDA-MB-468, resulting 
Figure 1: Pharmacologic properties of [89Zr]DFO-CR011 in vitro. (A) Competitive binding study in MDA-MB-468. (B) Cell 
uptake and blocking studies in cell lines with varying gpNMB expression. (C) The cell uptake of [89Zr]DFO-CR011 is correlated with 
gpNMB expression in whole cell lysates (Pearson’s r = 0.95). (D) Rate of cellular internalization at 37ºC showed 50% of bound [89Zr]DFO-
CR011 internalized within 30 – 60 min. The reaction at 4ºC significantly reduced cellular internalization.
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in an average Kd of 25 ± 5 nM in these cell lines 
(Supplementary Figure 5A). This Kd value is in agreement 
with previous studies reporting a Kd value of 52 nM for 
native CR011 against recombinant gpNMB using non-
radioactive methods [20]. Based on these saturation 
assays, we interpolated Bmax values to determine the 
number of gpNMB molecules per cell. We found that 
there are about 605 ± 28 k gpNMB per MDA-MB-157 
cell; 246 ± 5 k in MDA-MB-468; and 637 ± 12 k in SK-
Mel2 (Supplementary Figure 5). Further, cell uptake 
studies showed [89Zr]DFO-CR011 bound specifically 
to MDA-MB-157 and MDA-MB-468 cells at 2 hrs of 
incubation with 14 ± 1 and 3 ± 0.3 % bound/million cells, 
respectively, and can delineate different expression levels 
of gpNMB (Figure 1B). The high uptake in MDA-MB-157 
was similar to that of the SK-Mel2 positive control with 
13 ± 0.6 % bound/million cells. Blocking with excess 
unlabeled CR011 significantly reduced [89Zr]DFO-CR011 
uptake in MDA-MB-157, MDA-MB-468, and SK-Mel2 
to 2 ± 0.6, 1 ± 0.2, and 0.8 ± 0.1 % bound/million cells, 
respectively. As expected, the uptake in gpNMB-negative 
MDA-MB-231 cells was minimal with 0.3 ± 0.03 % 
bound/million cells. The cell uptake of [89Zr]DFO-CR011 
in these cell lines was correlated with gpNMB expression 
on whole cell lysates, as determined via ELISA. The 
Table 1: Biodistribution of [89Zr]DFO-CR011 in MDA-MB-468 xenografts under non-blocking and blocking 
conditions from 1 – 12 days post injection (n = 3 per group)
Organ 1 day p.i. (%ID/g ± SD)
1 day p.i. blocking 
(%ID/g ± SD)
4 days p.i. (%ID/g 
± SD)
4 days p.i. blocking 
(%ID/g ± SD)
7 days p.i. (%ID/g 
± SD)
12 days p.i. 
(%ID/g ± SD)
Blood 23.4 ± 2.8 22.6 ± 1.6 17.7 ± 4.8 14.7 ± 1.9 13.1 ± 1.2 9.2 ± 0.6
Lung 9.7 ± 0.6 10.6 ± 1.6 8.6 ± 3.0 7.4 ± 1.3 7.0 ± 0.9 5.8 ± 0.7
Liver 12.7 ± 6.1 7.1 ± 2.8 9.6 ± 3.7 5.2 ± 0.9 6.7 ± 0.9 7.4 ± 3.3
Spleen 5.6 ± 1.0 6.9 ± 1.1 7.8 ± 3.4 6.5 ± 2.2 7.4 ± 1.3 7.7 ± 1.5
Kidney 5.6 ± 0.6 5.7 ± 1.0 5.1 ± 1.4 4.5 ± 0.7 4.5 ± 0.5 4.5 ± 0.2
Muscle 3.0 ± 0.6 2.9 ± 0.3 2.3 ± 0.7 2.2 ± 0.3 2.0 ± 0.4 1.7 ± 0.1
Heart 8.3 ± 2.4 6.9 ± 0.9 5.9 ± 2.3 4.6 ± 1.1 5.1 ± 0.5 2.9 ± 0.1
Bone 2.4 ± 0.2 2.2 ± 0.3 5.4 ± 1.9 4.3 ± 0.6 6.7 ± 0.8 10.3 ± 2.1
Marrow 7.8 ± 0.6 7.5 ± 0.5 6.9 ± 1.9 5.5 ± 1.4 6.4 ± 2.1 5.9 ± 0.6
Tumor 13.3 ± 1.9 11.0 ± 2.2 22.1 ± 2.0 10.0 ± 2.0 24.5 ± 7.7 23.5 ± 2.9
Stomach 1.0 ± 0.3 1.0 ± 0.2 0.8 ± 0.2 0.8 ± 0.5 1.3 ± 0.8 0.7 ± 0.2
Values represent percent injected dose per gram ± standard deviation (%ID/g ± SD).
Figure 2: PET/CT imaging of [89Zr]DFO-CR011 in TNBC xenograft models at 4 days post-injection. (A) Maximum 
Intensity Projections of representative mice. (B) Mean SUV in tumors at 4 and 7 days show significantly higher [89Zr]DFO-CR011 uptake 
in MDA-MB-468 at both time points. (C) Biodistribution study post PET imaging at 7 days. Similar [89Zr]DFO-CR011 uptake in normal 
organs were observed for both xenograft models.
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Pearson’s correlation coefficient was determined to be 
0.95 (Figure 1C).
As the effectiveness of antibody drug conjugates 
rely on the internalization of the antibody to the cell 
to deliver the drug, we evaluated the rate of cellular 
internalization of [89Zr]DFO-CR011 in MDA-MB-468 
cells. We found that 50% of bound [89Zr]DFO-CR011 was 
internalized within 30 – 60 min at 37°C, whereas [89Zr]
DFO-CR011 did not reach 50% internalization within 
the 24-hr time point at 4°C (Figure 1D). Taken together, 
these results show the feasibility of [89Zr]DFO-CR011 as 
an excellent imaging agent for gpNMB. Its specificity, 
high affinity, and rapid cellular internalization indicate 
that [89Zr]DFO-CR011 could be an excellent companion 
diagnostic agent for CDX-011 and a PET imaging agent 
for gpNMB in vivo.
[89Zr]DFO-CR011 is specific to gpNMB in cell-
derived xenograft models of TNBC
The pharmacokinetic properties were determined 
via biodistribution studies at 1, 4, 7, and 12 days post 
injection (p.i.) in MDA-MB-468 xenografts, where 
the tumor uptake of [89Zr]DFO-CR011 increased from 
13.3 ± 1.8 % ID/g at 1 day p.i. to 22.1 ± 2.0 % ID/g at 
4 days p.i. (Table 1). The tumor uptake was constant 
at 7 and 12 days p.i., with 24.5 ± 7.7 and 23.5 ± 2.9 % 
ID/g, respectively, confirming the residualizing property 
of Zr-89. The uptake in the blood, heart, and liver also 
decreased, showing the slow clearance or metabolism 
of [89Zr]DFO-CR011 over time. Metabolism studies are 
needed for future investigations to elucidate the cause of 
decreased uptake of this radiotracer in these organs over 
time. The biodistribution of this fully human [89Zr]DFO-
CR011 in normal organs of mice was consistent with 
that of other 89Zr-labeled antibodies that are specific for 
their human antigens [23, 24]. As expected, radioactive 
uptake in the bone had a steady increase over the 12 days 
from 2.4 ± 0.2 %ID/g at 1 day p.i. to 10.3 ± 2.1 %ID/g at 
12 days p.i., which is likely due to the decomplexation 
of Zr-89 from the antibody-DFO conjugate (Table 1) 
[25]. Additionally, the specificity of [89Zr]DFO-CR011 
was confirmed under blocking conditions from pre-
administration of 1 mg of unlabeled CR011 at 1 day prior 
to the injection of [89Zr]DFO-CR011 in a subset of mice. 
The tumor uptake of [89Zr]DFO-CR011 was reduced 
by 50% at 4 days p.i. (Table 1). Based on these studies, 
we performed PET imaging at 4 and 7 days p.i., where 
optimal tumor-to-background (T/B) ratios were observed 
in addition to maintaining imaging quality. PET imaging 
of [89Zr]DFO-CR011 in MDA-MB-468 was compared to 
that in the gpNMB-negative MDA-MB-231 xenograft. 
Figure 2A shows maximum intensity projections of 
MDA-MB-468 and MDA-MB-231, with higher tumor 
uptake in the gpNMB-positive xenograft. Quantification 
of tumor uptake at 4 and 7 days p.i. determined that [89Zr]
DFO-CR011 had a mean SUV of 2.9 ± 0.6 in the gpNMB-
positive xenograft versus 1.6 ± 0.5 in the gpNMB-negative 
model (P < 0.05) at 4 days p.i. (Figure 2B). The same 
difference in uptake was observed at 7 days p.i. with a 
mean of 2.9 ± 0.5 for MDA-MB-468, versus 1.4 ± 0.7 
for MDA-MB-231 (P < 0.05). A post-PET biodistribution 
Figure 3: Immunofluorescence staining of gpNMB in MDA-MB-468 (A) and MDA-MB-231 (B) tumor sections. Scale bars represent 
50 μm. DAPI stained nuclei are marked blue and gpNMB stained (positive) membrane fragments are shown as green.
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Table 2: Residence times of [89Zr]DFO-CR011 in 
MDA-MB-468 xenografts
Organ Residence time, hrs
Blood 23.6 ± 3.4
Lungs 2.65 ± 0.41
Liver 5.54 ± 2.04
Spleen 0.45 ± 0.10
Kidneys 0.56 ± 0.07
Muscle 16.3 ± 3.3
Fat 9.4 ± 3.2
Heart 0.66 ± 0.15
Bone 7.68 ± 1.59
Red Marrow 3.61 ± 0.62
Pancreas 0.08 ± 0.01
Stomach 0.06 ± 0.02
Small Intestine 0.39 ± 0.07
Upper L. Intestine 0.11 ± 0.02
Lower L. Intestine 0.08 ± 0.02
Heart Content 2.36 ± 0.34
Remainder of the body 72.5
study was performed to compare [89Zr]DFO-CR011 uptake 
in normal organs and validate quantification from imaging 
studies. No differences in organ uptake were observed for 
these different models, with the exception of the tumor 
(Figure 2C).
Interestingly, the tumor uptake in MDA-MB-468 
from the biodistribution study following PET (post-PET 
biodistribution) was about 50 % lower than that from the 
biodistribution in the pharmacokinetic study at 7 days 
p.i., with 11.9 ± 1.5 and 24.5 ± 7.7 % ID/g, respectively. 
In the post-PET biodistribution study, we injected 20 μg 
(3.7 MBq) of [89Zr]DFO-CR011 in order to obtain a high 
imaging signal, compared with 10 μg (1.9 MBq) of [89Zr]
DFO-CR011 for the pharmacokinetic study. As the specific 
activity is equivalent in both studies (185 MBq/mg), the 
20 μg-injected dose in the post-PET biodistribution study 
likely saturated gpNMB and, thus, yielded a lower % ID/g 
at 7 days p.i. To test this hypothesis, we then conducted 
a biodistribution study in a small subset of mice injected 
with 2 μg (0.37 MBq) of [89Zr]DFO-CR011 at 7 days 
p.i. to determine if a lower mass of antibody would 
increase tumor uptake. We found no significant increase 
in the tumor uptake for the 2 μg dose (20.4 ± 4.6 % ID/g) 
compared with the 10 μg dose (Supplementary Figure 6). 
Rather, we observed a trend of increasing tumor:blood 
ratios with decreasing mass of antibody. Tumor:blood 
ratios determined from biodistribution studies at 7 days 
p.i. were 1.55 ± 0.05, 1.86 ± 0.22, and 1.92 ± 0.14 which 
correspond to the 20, 10, and 2 μg of [89Zr]DFO-CR011, 
respectively. Tumor:blood ratios for the 20 and 2 μg 
doses were statistically significant (P = 0.03), which 
could be due to a blocking effect. However, other dose 
comparisons were not statistically significant (P > 0.05), 
and could be due to shed antigen. While CR011 would 
be able to bind to shed gpNMB, we did not test for the 
presence of this shed antigen in our animal models due 
to limited volume of blood samples. More investigations 
are needed to determine the role of specific activity, mass 
of antibody, and quantification of shed antigen in the 
translation of [89Zr]DFO-CR011 to the clinical setting 
in order to optimize the sensitivity of detecting gpNMB. 
Nevertheless, [89Zr]DFO-CR011 can differentiate low 
expression of gpNMB as compared with negative 
expression in vivo (Figure 2B). Immunofluorescence 
staining of gpNMB on these tumors ex vivo is consistent 
with the imaging and biodistribution studies (Figure 3). 
Raw data and H&E stains are shown in Supplementary 
Figure 7. Despite the weak intensity of extracellular 
gpNMB staining in the MDA-MB-468, PET using [89Zr]
DFO-CR011 was capable of detecting gpNMB in vivo.
Dosimetry of [89Zr]DFO-CR011 in MDA-MB-468 
xenografts
Data from biodistribution studies were used to 
determine radiation dosimetry. Organ residence times are 
presented in Table 2. Due to the long circulation time of 
antibodies, the blood residence times are observed to be the 
highest with 23.6 hrs. The decay-corrected uptake in the 
blood over time shows that the effective half-life of CR011 
was about 8 days (Supplementary Figure 8A), which is 
consistent with previous studies reporting a 10-day half-
life using non-radioactive methods [20]. Blood-rich 
organs such as liver and lungs also depict long residence 
times. The rate of tumor uptake was also determined to 
be 0.034% ID/g/hr, which corresponds to a half-life of 20 
hrs (Supplementary Figure 8B). However, the long blood 
residence time limits imaging at this earlier time point. The 
organ and whole body radiation dosimetry is presented in 
Table 3. The biodistribution, typical of antibodies, and the 
long tracer retention time leads to an approximately 0.54 
mSv/MBq dose in each organ. The heart appears to be the 
dose-limiting organ due to the long retention in the blood. 
A high radiation dose is also observed in the osteogenic 
cells. The effective dose is measured at 0.54 mSv/MBq. 
Under NRC CFR 361.1 regulation, these values indicate a 
maximum recommended dose of 90 MBq (2.2 mCi) would 
be feasible for patient studies.
Evaluation of [89Zr]DFO-CR011 in patient-
derived xenograft models of TNBC
A panel of PDX breast tumor tissues were screened 
for mRNA expression of gpNMB at different passages 
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(Supplementary Figure 9). WHIM-4 and WHIM-
5 models were selected for imaging studies, as these 
PDX models expressed high and low mRNA levels 
of gpNMB, respectively (Supplementary Figure 9). 
Immunohistochemistry confirmed the relative protein 
expression of gpNMB in earlier passages (A – D) of these 
models that were available (Data not shown). PET using 
[89Zr]DFO-CR011 was performed in passage E of WHIM-
4 and F of WHIM-5 at 4 and 7 days p.i., similarly to 
imaging of MDA-MB-468 and MDA-MB-231 xenograft 
models (Figure 4A). Total protein expression of gpNMB 
was then confirmed following PET studies using ELISA 
and IHC. This study shows that gpNMB expression was 
heterogeneous in WHIM5F (n = 3) and lost expression in 
WHIM4E (n = 5) (Figure 4A). Mean SUV of the [89Zr]
DFO-CR011 tumor uptake was correlated with total 
gpNMB expression obtained from ELISA (Figure 4B). 
Supplementary Figure 10 confirms the membrane and 
cytoplasmic staining of gpNMB although quantification 
using this technique was not performed due to the 
heterogeneous expression of gpNMB within each PDX 
tumor sample. Thus, we simplified our correlative analysis 
to total gpNMB expression using ELISA. Despite the 
heterogeneity of gpNMB expression, a positive correlation 
was determined between [89Zr]DFO-CR011 tumor uptake 
in vivo and total gpNMB expression ex vivo (r = 0.79, 
Figure 4B).
DISCUSSION
There is an unmet need to validate novel targets 
for TNBC. The gpNMB is an example of an emerging 
biomarker which is overexpressed in up to 40% of 
TNBC. For this reason, the anti-gpNMB antibody drug 
conjugate, CDX-011, has been accelerated into clinical 
trials for the treatment of patients with advanced 
TNBC, notably those who are refractory to standard 
of care chemotherapy and demonstrated efficacy in 
gpNMB over expressing tumors [9]. Incorporation 
of companion diagnostic imaging agents in clinical 
trials of CDX-011 could assist the selection of patient 
candidates. Currently, gpNMB expression is determined 
by IHC for patient eligibility. While IHC is a valuable 
tool, a significant limitation is the sampling of a small 
piece of the tumor often from an archival specimen 
which may not be accurately representative of the 
patients’ tumor lesion or distant lesions. In advanced 
TNBC, the heterogeneity of gpNMB expression in 
metastatic lesions is currently unknown. Further, IHC 
cannot delineate membrane from cytoplasmic gpNMB 
expression. PET imaging using [89Zr]DFO-CR011 
could provide information about the heterogeneity of 
gpNMB expression and quantify cell surface gpNMB, 
a requirement for CDX-011 therapy. While tissue 
distribution of the radiolabeled naked antibody may not 
be exactly the same as that of the ADC, the affinity for 
gpNMB is similar and is currently the best approach 
for a companion diagnostic imaging agent despite this 
inherent limitation. Additionally, shedding of gpNMB 
extracellular domain via the ADAM10 sheddase activity 
[26] might potentially render CDX-011 therapy less 
effective. PET imaging using [89Zr]DFO-CR011 could 
potentially predict the effectiveness of CDX-011.
In this study, we sought to evaluate [89Zr]DFO-
CR011 in preclinical models of TNBC to determine the 
feasibility of this radiopharmaceutical for translation to 
clinical trial as a companion diagnostic agent to CDX-
011. We chose Zr-89 over other radionuclides due to 
its favorable half-life (3.3 days) that matches the 8-day 
biological half-life of CR011 in mice (Supplementary 
Figure 6B) to allow for imaging at later time points. Its 
desired decay properties also permit high resolution 
imaging, and its residualizing property could minimize 
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the translocation of Zr-89 to other organs after cellular 
internalization. Leveraging established chemistries and 
the success of CDX-011 in Phase I/II clinical trials, 
we applied [89Zr]DFO-CR011 PET in triple negative 
breast cancer which currently lacks established targeted 
treatments. Our work can serve as the basis to translate 
[89Zr]DFO-CR011 to the clinic as a companion diagnostic 
agent to CDX-011 with the potential to accelerate its 
FDA-approval by providing a means to identify patients 
who might benefit from this treatment strategy. Our 
results show that [89Zr]DFO-CR011 binds specifically to 
gpNMB and can distinguish different levels of cell surface 
gpNMB expression based on our cell binding studies and 
imaging in vivo (Table 1, Figures 1, 2, and 4). Despite the 
heterogeneity observed in the clinically-relevant PDX 
models, the sensitivity of detecting gpNMB in these 
experiments and in the more established cell-derived 
xenograft models shows that [89Zr]DFO-CR011 shows 
promise in delineating the varying expression levels of 
gpNMB in patients whose ability to respond to CDX-011 
is dependent on the level of gpNMB expression [9]. Thus, 
PET using [89Zr]DFO-CR011 has the potential to predict 
response to CDX-011 in future investigations.
However, a limitation of this study is that we were 
unable to assess the selectivity of [89Zr]DFO-CR011 
for targeting gpNMB in the tumor versus gpNMB in 
normal organs, as the CR011 antibody binds selectively 
to human gpNMB. Despite this limitation, a dosimetry 
study in mice is still required for clinical translation 
to determine an estimated dose for human use (Table 
3). PET imaging in humans would be a more accurate 
way to assess the selectivity of [89Zr]DFO-CR011 for 
gpNMB-overexpressing tumors over normal organs. 
Thus, this concept warrants further investigation in a 
clinical setting. Toward this goal, we prepared [89Zr]
DFO-CR011 similarly to other 89Zr-labeled antibodies 
currently approved for clinical investigations [23, 27] to 
estimate the radiation dosimetry for human use, which is 
consistent with existing 89Zr-labeled antibodies that are 
currently being investigated in clinical trials [23].
In conclusion, this work presents the first time 
that gpNMB is imaged in vivo. PET imaging of 
gpNMB using [89Zr]DFO-CR011 in these preclinical 
studies demonstrates the feasibility of translating this 
radiopharmaceutical to a clinical trial to select patients 
with TNBC who might benefit from CDX-011. Further, 
imaging gpNMB in the metastatic setting will determine 
its overall expression throughout the body, and assess if 
heterogeneity of gpNMB plays a role in patient outcome. 
Lastly, PET imaging of gpNMB could be applied to other 
cancer types that overexpress this clinically-relevant target 
beyond triple negative breast cancer.
Figure 4: PET/CT imaging of [89Zr]DFO-CR011 in PDX models of TNBC at 7 days post-injection. (A) Maximum Intensity 
Projections of WHIM-4E and WHIM-5F. Mean SUV are shown as values next to the tumors. (B) Correlative study between mean SUV in 
the tumor and gpNMB expression via ELISA.
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MATERIALS AND METHODS
Cell lines and animal models
The human TNBC cell lines (MDA-MB-157, MDA-
MB-468 and MDA-MB-231) and the human melanoma 
cell line (SK-Mel2) were obtained from the American 
Type Culture Collection (ATCC) and were tested for 
mycoplasma. These cells were cultured using Iscove’s 
modified dulbecco’s medium (IMDM) supplemented with 
10% fetal bovine serum (FBS) and 10μg/mL gentamycin 
(complete medium) at 37ºC under humidified atmosphere 
with 5% CO2. All cell lines were passaged < 40 times 
prior to experiments. At the conclusion of this study, all 
cell lines were authenticated using Illumina sequencing 
and STARS analysis [28]. All cell studies were conducted 
using these conditions unless stated otherwise.
All animal studies were conducted in compliance 
with the Washington University Institutional Animal Care 
and Use Committee. Female NCI athymic NCr-nu/nu 
(5 – 7 weeks old) were obtained from Charles River and 
1.5% isoflurane was used as anesthesia. Xenografts were 
generated by inoculating the mice with 100 μL of ~107 cells 
suspended in PBS, subcutaneously. Tumor sizes reached 
between 100 - 500 mm3 at 4 weeks post inoculation for 
MDA-MB-468 xenografts and 200 – 500 mm3 for MDA-
MB-231 at 2 weeks post inoculation. In our hands, MDA-
MB-157 cells did not form tumors in this strain of mice and 
were only used for cell binding studies. PDX models were 
obtained from the HAMLET Core facility [29].
Preparation of [89Zr]DFO-CR011
CR011 (Celldex Therapeutics) was conjugated via 
lysine residues to desferrioxamine-p-benzyl-isothiocyanate 
(Macrocyclics, Inc.) metal chelate (DFO-Bz-NCS) with 
minor modifications from previous studies [23]. The 
conjugation buffer used in the current study was PBS (pH 
9) and the radiolabeling buffer was 10 mM sodium citrate 
buffer (pH 6.8) to reduce antibody aggregation. Zr-89 was 
produced in house with an effective specific activity of 
145 – 656 mCi/μmol. The highest specific activity of [89Zr]
DFO-CR011 was achieved at 370 MBq/mg. The ratio of 
DFO:CR011 was determined using a radioisotopic dilution 
assay as described previously [30], except that FeCl3 was 
used to compete with Zr-89. For cell-binding and animal 
studies, a specific activity of 185 MBq/mg was prepared 
to ensure ≥ 95% radiochemical yield. [89Zr]DFO-CR011 
was purified by buffer exchanging with 2 mM sodium 
citrate in saline. Protein aggregation was determined via 
size exclusion chromatography (Superose 12 10/300 GL) 
with a flow rate of 0.8 mL/min of 0.1 M sodium phosphate 
(pH 6.5) containing 0.15 M NaCl buffer. An AKTA fast 
protein liquid chromatography (FPLC) equipped with 
radioactivity (Lablogic) and UV (A280nm) detectors was 
used.
Characterization of the pharmacological 
properties of [89Zr]DFO-CR011 in vitro
The specificity of [89Zr]DFO-CR011 was evaluated 
in the TNBC cell lines which express high (MDA-
MB-157), moderate (MDA-MB-468), and negative 
(MDA-MB-231) levels of gpNMB. SKMel-2 melanoma 
cells were used as the positive control for gpNMB, as 
this cell line has much higher gpNMB expression levels 
than most breast cancer cell lines [12]. Each cell line 
was seeded in 6-well plates in complete medium at 1 × 
105cells per well. The medium was changed to 1 mL of 
starvation medium (1% FBS) and incubated for 24 hrs. All 
cell studies described in this work were conducted under 
these conditions. The medium was changed to 1 mL of 50 
ng/mL of [89Zr]DFO-CR011 (9.25 kBq) in complete media 
and was incubated for 2 hrs at 37ºC. Under blocking 
conditions, a final concentration of 5 μg/mL of unlabeled 
CR011 was added to the wells prior to the addition of 
[89Zr]DFO-CR011. Cells were washed with 1 mL of PBS, 
3×. Cells were harvested and assayed using an automatic 
gamma counter (Perkin Elmer), from which the percentage 
of cell-bound radiotracer was calculated and normalized to 
the number of cells.
The immunoreactivity of [89Zr]DFO-CR011 was 
determined using a competitive binding assay to compare 
the ability of unlabeled native CR011 and DFO-CR011 
conjugate to compete for binding to gpNMB with [89Zr]
DFO-CR011. MDA-MB-468 cells (500 μL of 5 × 105 
cells/mL) were seeded in 12-well plates exposed to 
varying concentrations of each competitor, native CR011 
or DFO-CR011, ranging from 0 – 25 μg/mL (3-fold 
dilutions) followed by a final concentration of 0.25 μg/
mL of [89Zr]DFO-CR011. The reaction was incubated 
overnight. Cells were washed with PBS, harvested, and 
assayed in a gamma counter as described above. The 
percentage of bound radiotracer (B) was normalized to the 
control reaction where no competitor was added (B0). B/B0 
× 100 was plotted against the log concentration of added 
competitor. Immunoreactivity was determined to be the 
ratio between the effective concentrations at 50% (EC50) 
binding between DFO-CR011 and CR011.
The rate of cellular internalization was determined 
by incubating 250 μL of 50 ng/mL of [89Zr]DFO-CR011 
with immobilized MDA-MB-468 cells at 37°C from 10 
min to 24 hrs. The control reaction was performed at 
4°C to show reduced internalization at this temperature. 
Previous methods were followed for this procedure [31].
Biodistribution, dosimetry, and PET imaging 
studies
The pharmacokinetic properties of [89Zr]
DFO-CR011 were first determined by conducting a 
biodistribution study in animals bearing MDA-MB-468 
tumors. [89Zr]DFO-CR011 with a specific activity of 185 
Oncotarget104312www.impactjournals.com/oncotarget
MBq/mg (100 μL of 1.85 MBq) was injected via tail vein 
of the mice. Animals were euthanized at 1, 4, 7, and 12 
days post injection (n = 3 per time point). Animals in the 
blocking study group (n = 3) received 100-fold excess 
(1 mg) of unlabeled CR011, 1 day prior to injection of 
the radiolabeled antibody, and were euthanized at 1 and 
4 days post injection of [89Zr]DFO-CR011. Animals were 
grouped randomly for these experiments. Organs were 
harvested, weighed, and assayed in a gamma counter, from 
which the percentage of injected dose per gram of organ 
(%ID/g) were calculated. T/B ratios were also calculated 
to determine the optimal PET time points.
Organ biodistribution data were integrated to 
generate the organ residence times. These residence times 
were then scaled to human organ weight and entered 
in OLINDA/EXM to generate human radiation dose 
estimates using the adult human female model and using 
the standard organ weight of ICRP 106 [32, 33]. Heart 
content was assigned 10% of the blood residence time 
and all unaccounted residence times was assigned to the 
remainder of the body.
For small animal PET imaging, 3.7 MBq of [89Zr]
DFO-CR011 (specific activity = 185 MBq/mg) was 
injected via tail vein. Static PET images were acquired 
for 20 min. using an Inveon PET/CT scanner (Siemens, 
Knoxville, TN) at 4 and 7 days post injection (p.i.). Images 
were reconstructed using maximum a posteriori algorithm 
and co-registered with CT images using Inveon Research 
Workplace Workstation software (Siemens). The [89Zr]
DFO-CR011 tumor uptake was quantified by drawing 
regions of interest on the tumor using CT as a guide. The 
measured radioactivity was decay-corrected to the time of 
injection of [89Zr]DFO-CR011 and the mean standardized 
uptake values (SUV) were calculated.
Immunofluorescence
gpNMB was stained using goat anti-human 
gpNMB (R&D Systems) primary antibody (1:500) at 4°C 
overnight, then with an anti-goat-Dylight 488 (Novus) 
secondary antibody (1:2500) at ambient temperature for 
1 hr. Slides were counterstained with DAPI mounting 
solution (Sigma). The high-resolution images of tissue 
slices were acquired using a digital whole slide scanner 
(Nanozoomer 2-HT, Hamamatsu. Bridgewater, NJ) using a 
20×/0.0.75 lens (Olympus, Center Valley, PA). The images 
were then quantified using the image analysis module of 
a digital pathology software Visiomorph (VisioPharm, 
Broomfield, CO).
Statistical evaluation
Data was analyzed using GraphPad Prism version 
6. A one-way ANOVA was used to analyze statistical 
significance when comparing samples with one variable, 
while a 2-way ANOVA was used to analyze samples 
with 2 variables. P < 0.05 was considered statistically 
significant.
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